However, next generation sequencing (NGS) data revealed that overall TP53 mutations were present in up to 16% of B-ALL patients and the incidence increased with age and hypodiploid karyotype [71–73]. This evidence concerns the gene TP53 and acute lymphoblastic leukemia.